\-\ Texto\\:\\ \ \(0\)\
\-\ sub\\-mandibular\\ and\\ cervical\\ regions\\ of\\ neck\\ enlarged\\ bilateraly\\,\\ with\\ left\\ greater\\ than\\ right\\.\\ \\ masses\\ were\\ firm\\,\\ mobile\\ and\\ non\\-tender\\.\\ no\\ changes\\ in\\ the\\ skin\\ overlying\\ the\\ masses\\.\\ \\ ears\\/eyes\\/nose\\/oropharynx\\ normal\\.\\ \\ lungs\\ clear\\ bilateraly\\.\\ \\ cardiovascular\\ exam\\ was\\ normal\\.\ \(0\)\
\-\ left\\ neck\\ dissection\\ for\\ debulking\\ of\\ mass\\.\\ \\ po\\ steroids\\ for\\ respiratory\\ symptoms\\.\ \(0\)\
\-\ significant\\ bilateral\\ neck\\ adenopathy\\.\\ confluent\\ left\\ parotid\\ and\\ periparotid\\ nodal\\ mass\\ with\\ largest\\ single\\ node\\ measuring\\ 2\\.7cm\\ x\\ 1\\.9cm\\.\\ \\ numerous\\ other\\ left\\ level\\ ii\\ and\\ iii\\ nodes\\ with\\ largest\\ measuring\\ 3\\.6cm\\ x\\ 2\\.1cm\\.\\ \\ mediastinal\\ and\\ bihilar\\ adenopathy\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ \\â\\€\\¢\\ sarcoidosis\ \(1\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ reactive\\ lymphadenopathy\\ \\(fungal\\,\\ etc\\.\\)\ \(0\)\
\-\ \\â\\€\\¢\\ catscratch\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ metastatic\\ carcinoma\ \(1\)\
\-\ 32\\ year\\ old\\ woman\\ with\\ a\\ 2\\ year\\ history\\ of\\ slowly\\ growing\\ lump\\ on\\ neck\\ along\\ and\\ progressive\\ shortness\\ of\\ breath\\.\\ \\ no\\ history\\ of\\ fevers\\,\\ weight\\ loss\\ or\\ recent\\ illness\\.\\ \\ patient\\ had\\ recently\\ undergone\\ dental\\ procedure\\ around\\ time\\ the\\ lump\\ was\\ first\\ noted\\.\ \(0\)\
\-\ sarciodosis\\ is\\ a\\ systemic\\ multisystem\\ granulomatous\\ disease\\ characterized\\ by\\ a\\ variable\\ clinical\\ presentation\\ and\\ course\\.\\ \\ cutaneous\\ lesions\\ are\\ present\\ in\\ about\\ one\\ fourth\\ of\\ patients\\.\\ although\\ any\\ organ\\ can\\ be\\ affected\\,\\ 90\\%\\ of\\ patients\\ demonstrate\\ thoracic\\ involvement\\ with\\ decreased\\ diffusion\\ capacity\\ being\\ the\\ most\\ common\\ abnormality\\ found\\ on\\ pulmonary\\ function\\ testing\\.\\ \\ there\\ is\\ a\\ strong\\ association\\ between\\ subcutaneous\\ sarciodosis\\ and\\ bilateral\\ hilar\\ lymphadenopathy\\ \\(72\\.7\\%\\)\\.\\ sarciodosis\\ is\\ a\\ diagnosis\\ of\\ exclusion\\ supported\\ by\\ three\\ elements\\:\\ 1\\.\\ compatible\\ clinical\\ and\\ radiologic\\ findings\\,\\ 2\\.\\ tissue\\ biopsy\\ specimen\\ that\\ reveals\\ noncaseating\\ epithelioid\\ granulomas\\,\\ and\\ 3\\.\\ absence\\ of\\ known\\ granulomagenic\\ agents\\.\\ \ \(0\)\
\-\ etiology\ \(199\)\
\-\ a\\ large\\ multi\\ centered\\ study\\ called\\ a\\ case\\ control\\ etiologic\\ study\\ of\\ sarciodosis\\ \\(access\\)\\ showed\\ that\\ environmental\\ factors\\ such\\ as\\ mold\\,\\ mildew\\,\\ must\\ odors\\ and\\ pesticides\\ were\\ associated\\ with\\ a\\ modestly\\ increased\\ risk\\ \\(or\\~1\\.5\\)\\ of\\ developing\\ sarciodosis\\.\\ genetics\\ and\\ host\\ factors\\ also\\ are\\ involved\\ in\\ the\\ pathogenesis\\ of\\ sarciodosis\\.\\ \\ in\\ the\\ us\\,\\ blacks\\ are\\ more\\ frequently\\ affected\\ and\\ the\\ access\\ trial\\ showed\\ that\\ affected\\ patients\\ were\\ five\\ times\\ more\\ likely\\ than\\ controls\\ to\\ report\\ a\\ sibling\\ with\\ the\\ disease\\.\\ \\ further\\,\\ recent\\ studies\\ have\\ identified\\ specific\\ genes\\ associated\\ with\\ sarciodosis\\.\\ \\ a\\ single\\-nucleotide\\ polymorphism\\ on\\ the\\ btnl2\\ gene\\ may\\ influence\\ t\\-lymphocyte\\ activation\\ and\\ regulation\\ and\\ make\\ people\\ carrying\\ this\\ polymorphism\\ more\\ susceptible\\ to\\ sarciodosis\\.\\ \\ a\\ second\\ gene\\ associated\\ with\\ sarciodosis\\ is\\ annexin\\ a11\\ on\\ chromosome\\ 10q22\\.3\\ responsible\\ for\\ calcium\\ signaling\\,\\ cell\\ division\\ and\\ apoptosis\\.\\ \\ \ \(0\)\
\-\ deficits\\ of\\ this\\ gene\\ have\\ been\\ associated\\ with\\ sarciodosis\\.\\ \\ further\\,\\ hla\\ haplotypes\\ and\\ t\\-cell\\ receptor\\ expression\\ play\\ an\\ intricate\\ role\\ in\\ the\\ development\\ of\\ the\\ disease\\.\ \(0\)\
\-\ biomarker\\ screening\ \(0\)\
\-\ in\\ an\\ attempt\\ to\\ aid\\ in\\ diagnosis\\ of\\ sarciodosis\\,\\ investigators\\ continue\\ to\\ search\\ for\\ potential\\ biomarkers\\ in\\ disease\\ activity\\.\\ chitotriosidase\\ is\\ an\\ enzyme\\ expressed\\ by\\ activated\\ macrophages\\ and\\ bargagli\\ et\\ al\\.\\ found\\ elevated\\ levels\\ of\\ this\\ enzyme\\ in\\ patients\\ with\\ sarciodosis\\,\\ with\\ \\>90\\%\\ exhibiting\\ elevated\\ levels\\ of\\ the\\ marker\\.\\ \\ a\\ second\\ marker\\ il\\-2\\,\\ a\\ cytokine\\ that\\ induces\\ t\\-cell\\ proliferation\\ and\\ activation\\ is\\ elevated\\ in\\ serum\\ of\\ patients\\ with\\ sarciodosis\\ and\\ may\\ have\\ prognostic\\ value\\.\\ \\ \ \(0\)\
\-\ diagnosis\ \(1295\)\
\-\ diagnosis\\ of\\ sarciodosis\\ is\\ best\\ supported\\ by\\ a\\ combination\\ of\\ radiographic\\ evidence\\ of\\ lymphadenopathy\\ and\\ tissue\\ specimens\\ that\\ show\\ noncaseating\\ granulomas\\.\\ \\ endobronchial\\ ultrasound\\ guided\\ transbronchial\\ needle\\ aspiration\\ when\\ compared\\ to\\ non\\-guided\\ transbronchial\\ needle\\ aspiration\\ had\\ a\\ diagnosis\\ yield\\ of\\ 83\\.3\\%\\ compared\\ to\\ 53\\.8\\%\\.\\ \\ \ \(0\)\
\-\ treatment\ \(1387\)\
\-\ therapy\\ for\\ patients\\ with\\ chronic\\ sarciodosis\\ requires\\ prolonged\\ treatment\\ often\\ with\\ steroids\\ which\\ cause\\ systemic\\ side\\ effects\\.\\ \\ tnf\\ inhibitors\\ have\\ been\\ investigated\\ for\\ the\\ treatment\\,\\ but\\ a\\ study\\ by\\ utz\\ et\\ al\\,\\ found\\ treatment\\ failure\\ in\\ nearly\\ 65\\%\\ of\\ participants\\.\\ \\ a\\ new\\ tnf\\-alpha\\ antagonist\\ ustekinumab\\,\\ approved\\ for\\ dosing\\ in\\ patients\\ with\\ ra\\,\\ psoriatic\\ arthritis\\,\\ and\\ ankylosing\\ spondylitis\\;\\ is\\ currently\\ being\\ tested\\ for\\ its\\ efficacy\\ in\\ treatment\\ of\\ sarciodosis\\ with\\ completion\\ of\\ the\\ study\\ anticipated\\ in\\ july\\ 2011\\.\\ \\ surgical\\ indication\\ for\\ patients\\ with\\ sarciodosis\\ remains\\ controversial\\.\\ \\ surgery\\ has\\ potential\\ to\\ reduce\\ symptoms\\ and\\ decrease\\ need\\ for\\ oral\\ steroids\\,\\ but\\ does\\ not\\ eradicate\\ or\\ prevent\\ recurrence\\ of\\ disease\\.\\ \\ corticosteroids\\ remain\\ the\\ cornerstone\\ for\\ treatment\\,\\ but\\ care\\ must\\ be\\ taken\\ to\\ assess\\ for\\ potential\\ adverse\\ effects\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sarciodosis\\:\\ 0\\.2072805161928499\ \(0\)\
\-\ patients\\:\\ 0\\.024471088236415226\ \(0\)\
\-\ polymorphism\\:\\ 0\\.024385943081511752\ \(0\)\
\-\ gene\\:\\ 0\\.02375301232617503\ \(0\)\
\-\ bilateraly\\:\\ 0\\.021346904938584755\ \(0\)\
\-\ noncaseating\\:\\ 0\\.020551103908289372\ \(0\)\
\-\ transbronchial\\:\\ 0\\.020551103908289372\ \(0\)\
\-\ activation\\:\\ 0\\.01900306576738917\ \(0\)\
\-\ t\\-cell\\:\\ 0\\.01900306576738917\ \(0\)\
\-\ enzyme\\:\\ 0\\.01863368432167818\ \(0\)\
\-\ potential\\:\\ 0\\.017074846714415278\ \(0\)\
\-\ steroids\\:\\ 0\\.016679368789916004\ \(0\)\
\-\ \\%\\:\\ 0\\.01654208326428222\ \(0\)\
\-\ supported\\:\\ 0\\.015835341550783356\ \(0\)\
\-\ study\\:\\ 0\\.015555360203927853\ \(0\)\
\-\ marker\\:\\ 0\\.015373227900262838\ \(0\)\
\-\ affected\\:\\ 0\\.015342425774065326\ \(0\)\
\-\ granulomas\\:\\ 0\\.015168226594166789\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.01507773806503906\ \(0\)\
\-\ access\\:\\ 0\\.014977374944133728\ \(0\)\
\-\ treatment\\:\\ 0\\.014353667714530182\ \(0\)\
\-\ neck\\:\\ 0\\.013882396332052462\ \(0\)\
\-\ lump\\:\\ 0\\.013794957199107618\ \(0\)\
\-\ effects\\:\\ 0\\.013794957199107618\ \(0\)\
\-\ diagnosis\\:\\ 0\\.013569981540666803\ \(0\)\
\-\ largest\\:\\ 0\\.013403116211381403\ \(0\)\
\-\ sub\\-mandibular\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ ears\\/eyes\\/nose\\/oropharynx\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ periparotid\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ 72\\.7\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ granulomagenic\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ mold\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ mildew\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ odors\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ modestly\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ or\\~1\\.5\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ single\\-nucleotide\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ btnl2\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ t\\-lymphocyte\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ annexin\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ a11\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ 10q22\\.3\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ haplotypes\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ intricate\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ biomarker\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ chitotriosidase\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ bargagli\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ cytokine\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ non\\-guided\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ 83\\.3\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ 53\\.8\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ utz\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ ustekinumab\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ eradicate\\:\\ 0\\.012192971540755876\ \(0\)\
\-\ for\\:\\ 0\\.012101380060460002\ \(0\)\
\-\ needle\\:\\ 0\\.012032117027142226\ \(0\)\
\-\ elevated\\:\\ 0\\.012030358345888227\ \(0\)\
\-\ disease\\:\\ 0\\.011591182914653147\ \(0\)\
\-\ systemic\\:\\ 0\\.011308798354783286\ \(0\)\
\-\ 2\\.7cm\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ 3\\.6cm\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ bihilar\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ catscratch\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ pesticides\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ biomarkers\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ il\\-2\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ participants\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ tnf\\-alpha\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ antagonist\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ cornerstone\\:\\ 0\\.011234261747450281\ \(0\)\
\-\ found\\:\\ 0\\.011174380142954823\ \(0\)\
\-\ associated\\:\\ 0\\.011156086096308172\ \(0\)\
\-\ 90\\:\\ 0\\.011142535770911349\ \(0\)\
\-\ aspiration\\:\\ 0\\.011142535770911349\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.01083689039831181\ \(0\)\
\-\ must\\:\\ 0\\.010776037339248612\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.010676877915256535\ \(0\)\
\-\ multisystem\\:\\ 0\\.010673452469292377\ \(0\)\
\-\ multi\\:\\ 0\\.010673452469292377\ \(0\)\
\-\ controls\\:\\ 0\\.010673452469292377\ \(0\)\
\-\ regulation\\:\\ 0\\.010673452469292377\ \(0\)\
\-\ signaling\\:\\ 0\\.010673452469292377\ \(0\)\
\-\ hla\\:\\ 0\\.010673452469292377\ \(0\)\
\-\ activated\\:\\ 0\\.010673452469292377\ \(0\)\
\-\ tnf\\:\\ 0\\.010673452469292377\ \(0\)\
\-\ factors\\:\\ 0\\.010619044762229388\ \(0\)\
\-\ adenopathy\\:\\ 0\\.010525264536293894\ \(0\)\
\-\ 2\\.1cm\\:\\ 0\\.010275551954144686\ \(0\)\
\-\ environmental\\:\\ 0\\.010275551954144686\ \(0\)\
\-\ apoptosis\\:\\ 0\\.010275551954144686\ \(0\)\
\-\ investigators\\:\\ 0\\.010275551954144686\ \(0\)\
\-\ have\\:\\ 0\\.010237555067026788\ \(0\)\
\-\ that\\:\\ 0\\.010207335605524366\ \(0\)\
\-\ al\\:\\ 0\\.010020917214595542\ \(0\)\
\-\ compared\\:\\ 0\\.010005591681053036\ \(0\)\
\-\ etiologic\\:\\ 0\\.00996691633683596\ \(0\)\
\-\ induces\\:\\ 0\\.00996691633683596\ \(0\)\
\-\ by\\:\\ 0\\.009840047740282675\ \(0\)\
\-\ levels\\:\\ 0\\.009757265264929359\ \(0\)\
\-\ 1\\.9cm\\:\\ 0\\.009714742675986782\ \(0\)\
\-\ blacks\\:\\ 0\\.009714742675986782\ \(0\)\
\-\ influence\\:\\ 0\\.009714742675986782\ \(0\)\
\-\ investigated\\:\\ 0\\.009714742675986782\ \(0\)\
\-\ approved\\:\\ 0\\.009714742675986782\ \(0\)\
\-\ 2011\\.\\:\\ 0\\.009714742675986782\ \(0\)\
\-\ et\\:\\ 0\\.009674684454003546\ \(0\)\
\-\ genes\\:\\ 0\\.009501532883694585\ \(0\)\
\-\ anticipated\\:\\ 0\\.009501532883694585\ \(0\)\
\-\ measuring\\:\\ 0\\.009453266175515201\ \(0\)\
\-\ a\\:\\ 0\\.009325306543452589\ \(0\)\
\-\ epithelioid\\:\\ 0\\.00931684216083909\ \(0\)\
\-\ expressed\\:\\ 0\\.00931684216083909\ \(0\)\
\-\ exhibiting\\:\\ 0\\.00931684216083909\ \(0\)\
\-\ dosing\\:\\ 0\\.00931684216083909\ \(0\)\
\-\ sibling\\:\\ 0\\.009153933397828877\ \(0\)\
\-\ second\\:\\ 0\\.0090791948416016\ \(0\)\
\-\ host\\:\\ 0\\.009008206543530363\ \(0\)\
\-\ carrying\\:\\ 0\\.009008206543530363\ \(0\)\
\-\ expression\\:\\ 0\\.009008206543530363\ \(0\)\
\-\ capacity\\:\\ 0\\.008876380568697273\ \(0\)\
\-\ yield\\:\\ 0\\.008876380568697273\ \(0\)\
\-\ more\\:\\ 0\\.008867951490921852\ \(0\)\
\-\ chromosome\\:\\ 0\\.008756032882681187\ \(0\)\
\-\ receptor\\:\\ 0\\.008756032882681187\ \(0\)\
\-\ inhibitors\\:\\ 0\\.008756032882681187\ \(0\)\
\-\ susceptible\\:\\ 0\\.008645323743437015\ \(0\)\
\-\ \\,\\:\\ 0\\.008611800147852849\ \(0\)\
\-\ macrophages\\:\\ 0\\.00854282309038899\ \(0\)\
\-\ adverse\\:\\ 0\\.00854282309038899\ \(0\)\
\-\ genetics\\:\\ 0\\.008447397265372459\ \(0\)\
\-\ division\\:\\ 0\\.008447397265372459\ \(0\)\
\-\ debulking\\:\\ 0\\.008358132367533496\ \(0\)\
\-\ play\\:\\ 0\\.008358132367533496\ \(0\)\
\-\ endobronchial\\:\\ 0\\.008358132367533496\ \(0\)\
\-\ specimens\\:\\ 0\\.008274280885076462\ \(0\)\
\-\ efficacy\\:\\ 0\\.008274280885076462\ \(0\)\
\-\ being\\:\\ 0\\.008237311139144008\ \(0\)\
\-\ in\\:\\ 0\\.008159835715025683\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.008120441832365226\ \(0\)\
\-\ were\\:\\ 0\\.008050980650165648\ \(0\)\
\-\ parotid\\:\\ 0\\.008049496750224767\ \(0\)\
\-\ masses\\:\\ 0\\.00799057371506525\ \(0\)\
\-\ recent\\:\\ 0\\.007946664035518112\ \(0\)\
\-\ nodal\\:\\ 0\\.007917670775391678\ \(0\)\
\-\ exclusion\\:\\ 0\\.007917670775391678\ \(0\)\
\-\ prognostic\\:\\ 0\\.007917670775391678\ \(0\)\
\-\ completion\\:\\ 0\\.007917670775391678\ \(0\)\
\-\ undergone\\:\\ 0\\.007856188392859403\ \(0\)\
\-\ people\\:\\ 0\\.007856188392859403\ \(0\)\
\-\ tested\\:\\ 0\\.007856188392859403\ \(0\)\
\-\ x\\:\\ 0\\.0077982471240594115\ \(0\)\
\-\ confluent\\:\\ 0\\.007797323089375591\ \(0\)\
\-\ showed\\:\\ 0\\.007750493133952135\ \(0\)\
\-\ controversial\\:\\ 0\\.007740861132916041\ \(0\)\
\-\ responsible\\:\\ 0\\.007686613950131419\ \(0\)\
\-\ search\\:\\ 0\\.007686613950131419\ \(0\)\
\-\ july\\:\\ 0\\.00763441432636538\ \(0\)\
\-\ but\\:\\ 0\\.007562254361135011\ \(0\)\
\-\ further\\:\\ 0\\.007517134555464062\ \(0\)\
\-\ indication\\:\\ 0\\.007488687472066864\ \(0\)\
\-\ trial\\:\\ 0\\.007443335020029533\ \(0\)\
\-\ aid\\:\\ 0\\.007443335020029533\ \(0\)\
\-\ dental\\:\\ 0\\.0073994225742279\ \(0\)\
\-\ clinical\\:\\ 0\\.007273332780265572\ \(0\)\
\-\ guided\\:\\ 0\\.007198617581358608\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.007198617581358608\ \(0\)\
\-\ ankylosing\\:\\ 0\\.007161732039059631\ \(0\)\
\-\ proliferation\\:\\ 0\\.007125804671973516\ \(0\)\
\-\ psoriatic\\:\\ 0\\.007125804671973516\ \(0\)\
\-\ specimen\\:\\ 0\\.007090786956919172\ \(0\)\
\-\ spondylitis\\:\\ 0\\.007056633965784496\ \(0\)\
\-\ role\\:\\ 0\\.0069907583793539915\ \(0\)\
\-\ organ\\:\\ 0\\.006927878193908961\ \(0\)\
\-\ agents\\:\\ 0\\.006927878193908961\ \(0\)\
\-\ centered\\:\\ 0\\.006927878193908961\ \(0\)\
\-\ cutaneous\\:\\ 0\\.006867732810866446\ \(0\)\
\-\ strong\\:\\ 0\\.006867732810866446\ \(0\)\
\-\ attempt\\:\\ 0\\.006782151339610446\ \(0\)\
\-\ po\\:\\ 0\\.006754761813612963\ \(0\)\
\-\ mobile\\:\\ 0\\.006727904156825824\ \(0\)\
\-\ value\\:\\ 0\\.006701558105690702\ \(0\)\
\-\ reduce\\:\\ 0\\.006675704533059784\ \(0\)\
\-\ cardiovascular\\:\\ 0\\.006625403503777799\ \(0\)\
\-\ remain\\:\\ 0\\.006625403503777799\ \(0\)\
\-\ illness\\:\\ 0\\.0065768677917290175\ \(0\)\
\-\ growing\\:\\ 0\\.00652997767876127\ \(0\)\
\-\ compatible\\:\\ 0\\.00652997767876127\ \(0\)\
\-\ nearly\\:\\ 0\\.006507115573711185\ \(0\)\
\-\ elements\\:\\ 0\\.006484625226723937\ \(0\)\
\-\ ra\\:\\ 0\\.006462494740767588\ \(0\)\
\-\ been\\:\\ 0\\.006430967882334692\ \(0\)\
\-\ slowly\\:\\ 0\\.0064192685395170965\ \(0\)\
\-\ etc\\:\\ 0\\.006398151703928177\ \(0\)\
\-\ continue\\:\\ 0\\.0063773524267988005\ \(0\)\
\-\ make\\:\\ 0\\.006316767886469072\ \(0\)\
\-\ variable\\:\\ 0\\.0062971487509338635\ \(0\)\
\-\ requires\\:\\ 0\\.006277804017912093\ \(0\)\
\-\ prolonged\\:\\ 0\\.006277804017912093\ \(0\)\
\-\ non\\-tender\\:\\ 0\\.0062587261173141185\ \(0\)\
\-\ is\\:\\ 0\\.006221751351421584\ \(0\)\
\-\ called\\:\\ 0\\.006203022245754035\ \(0\)\
\-\ than\\:\\ 0\\.0061937727660256545\ \(0\)\
\-\ developing\\:\\ 0\\.006184941911635981\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.006149475202627216\ \(0\)\
\-\ radiologic\\:\\ 0\\.006149475202627216\ \(0\)\
\-\ remains\\:\\ 0\\.006149475202627216\ \(0\)\
\-\ combination\\:\\ 0\\.005953885086375724\ \(0\)\
\-\ hilar\\:\\ 0\\.005938768806248213\ \(0\)\
\-\ assess\\:\\ 0\\.005923815948566034\ \(0\)\
\-\ 32\\:\\ 0\\.0058943866284453085\ \(0\)\
\-\ five\\:\\ 0\\.0058943866284453085\ \(0\)\
\-\ need\\:\\ 0\\.0058943866284453085\ \(0\)\
\-\ symptoms\\:\\ 0\\.005891168677449901\ \(0\)\
\-\ characterized\\:\\ 0\\.005879903502764402\ \(0\)\
\-\ prevent\\:\\ 0\\.005865570463987712\ \(0\)\
\-\ dissection\\:\\ 0\\.0058096789863419625\ \(0\)\
\-\ firm\\:\\ 0\\.005796052020307368\ \(0\)\
\-\ calcium\\:\\ 0\\.0057825580024023\ \(0\)\
\-\ 65\\:\\ 0\\.00576919436352023\ \(0\)\
\-\ association\\:\\ 0\\.005742848312385106\ \(0\)\
\-\ bilateral\\:\\ 0\\.005736701879154755\ \(0\)\
\-\ fungal\\:\\ 0\\.005729861119646738\ \(0\)\
\-\ times\\:\\ 0\\.005729861119646738\ \(0\)\
\-\ and\\:\\ 0\\.005726427568244847\ \(0\)\
\-\ fourth\\:\\ 0\\.005716994739754189\ \(0\)\
\-\ testing\\:\\ 0\\.005716994739754189\ \(0\)\
\-\ granulomatous\\:\\ 0\\.005704246945694821\ \(0\)\
\-\ serum\\:\\ 0\\.005704246945694821\ \(0\)\
\-\ fevers\\:\\ 0\\.0056181579984234216\ \(0\)\
\-\ tissue\\:\\ 0\\.005602824864322528\ \(0\)\
\-\ reactive\\:\\ 0\\.005594514245505994\ \(0\)\
\-\ iii\\:\\ 0\\.00554840578040559\ \(0\)\
\-\ recently\\:\\ 0\\.005514805928996123\ \(0\)\
\-\ regions\\:\\ 0\\.0054083591224454615\ \(0\)\
\-\ node\\:\\ 0\\.0054083591224454615\ \(0\)\
\-\ deficits\\:\\ 0\\.0054083591224454615\ \(0\)\
\-\ decrease\\:\\ 0\\.0054083591224454615\ \(0\)\
\-\ control\\:\\ 0\\.005388018669624306\ \(0\)\
\-\ overlying\\:\\ 0\\.005348213739402946\ \(0\)\
\-\ nodes\\:\\ 0\\.0053384389576282675\ \(0\)\
\-\ numerous\\:\\ 0\\.005300016324008523\ \(0\)\
\-\ diffusion\\:\\ 0\\.005290575155169795\ \(0\)\
\-\ report\\:\\ 0\\.005290575155169795\ \(0\)\
\-\ left\\:\\ 0\\.005289655708287219\ \(0\)\
\-\ may\\:\\ 0\\.005184864091004492\ \(0\)\
\-\ recurrence\\:\\ 0\\.005156185461596285\ \(0\)\
\-\ development\\:\\ 0\\.005147673890953992\ \(0\)\
\-\ frequently\\:\\ 0\\.005122449011908652\ \(0\)\
\-\ had\\:\\ 0\\.005100552750320078\ \(0\)\
\-\ ii\\:\\ 0\\.005097675946118154\ \(0\)\
\-\ arthritis\\:\\ 0\\.00504942247585475\ \(0\)\
\-\ screening\\:\\ 0\\.005041541395474892\ \(0\)\
\-\ mediastinal\\:\\ 0\\.005018164063797709\ \(0\)\
\-\ function\\:\\ 0\\.005010458607297771\ \(0\)\
\-\ etiology\\:\\ 0\\.005002795840526518\ \(0\)\
\-\ oral\\:\\ 0\\.004980059012942618\ \(0\)\
\-\ shortness\\:\\ 0\\.004972562377438691\ \(0\)\
\-\ best\\:\\ 0\\.004972562377438691\ \(0\)\
\-\ involved\\:\\ 0\\.004957689913017859\ \(0\)\
\-\ us\\:\\ 0\\.004957689913017859\ \(0\)\
\-\ procedure\\:\\ 0\\.004950313224255255\ \(0\)\
\-\ taken\\:\\ 0\\.004928416315241865\ \(0\)\
\-\ around\\:\\ 0\\.004921193709458807\ \(0\)\
\-\ absence\\:\\ 0\\.004914008623874983\ \(0\)\
\-\ respiratory\\:\\ 0\\.0049068606706821165\ \(0\)\
\-\ an\\:\\ 0\\.00490317371072502\ \(0\)\
\-\ specific\\:\\ 0\\.004885635816360318\ \(0\)\
\-\ are\\:\\ 0\\.004833501545765982\ \(0\)\
\-\ single\\:\\ 0\\.004790678133458412\ \(0\)\
\-\ to\\:\\ 0\\.004725511573366377\ \(0\)\
\-\ currently\\:\\ 0\\.0046835031742905354\ \(0\)\
\-\ progressive\\:\\ 0\\.00467142339563389\ \(0\)\
\-\ failure\\:\\ 0\\.004629956131163716\ \(0\)\
\-\ reveals\\:\\ 0\\.004624132434709576\ \(0\)\
\-\ about\\:\\ 0\\.004556096135690528\ \(0\)\
\-\ thoracic\\:\\ 0\\.004556096135690528\ \(0\)\
\-\ skin\\:\\ 0\\.0045395974208008\ \(0\)\
\-\ radiographic\\:\\ 0\\.004485981178131029\ \(0\)\
\-\ lungs\\:\\ 0\\.004475502901770783\ \(0\)\
\-\ course\\:\\ 0\\.004459932840187609\ \(0\)\
\-\ its\\:\\ 0\\.004459932840187609\ \(0\)\
\-\ greater\\:\\ 0\\.0044394417118540815\ \(0\)\
\-\ activity\\:\\ 0\\.0044343660149122254\ \(0\)\
\-\ breath\\:\\ 0\\.004419249734784714\ \(0\)\
\-\ studies\\:\\ 0\\.0044142474658079665\ \(0\)\
\-\ clear\\:\\ 0\\.004370022978072816\ \(0\)\
\-\ abnormality\\:\\ 0\\.004360384431300902\ \(0\)\
\-\ involvement\\:\\ 0\\.0043318653618642\ \(0\)\
\-\ cervical\\:\\ 0\\.004294732235949694\ \(0\)\
\-\ risk\\:\\ 0\\.004281060369791268\ \(0\)\
\-\ care\\:\\ 0\\.0042630389309388\ \(0\)\
\-\ weight\\:\\ 0\\.00423643953684767\ \(0\)\
\-\ identified\\:\\ 0\\.004223329240921607\ \(0\)\
\-\ biopsy\\:\\ 0\\.00419321333559718\ \(0\)\
\-\ of\\:\\ 0\\.004189624924962239\ \(0\)\
\-\ new\\:\\ 0\\.004118655569572004\ \(0\)\
\-\ side\\:\\ 0\\.00409467012692126\ \(0\)\
\-\ presentation\\:\\ 0\\.004071093547013945\ \(0\)\
\-\ 3\\.\\:\\ 0\\.004044086047220923\ \(0\)\
\-\ enlarged\\:\\ 0\\.0040326709133942\ \(0\)\
\-\ does\\:\\ 0\\.0040326709133942\ \(0\)\
\-\ on\\:\\ 0\\.004004929528992686\ \(0\)\
\-\ cause\\:\\ 0\\.003998980119712263\ \(0\)\
\-\ \\(\\:\\ 0\\.003996468748237126\ \(0\)\
\-\ although\\:\\ 0\\.0039916034309496595\ \(0\)\
\-\ this\\:\\ 0\\.003988121217071092\ \(0\)\
\-\ three\\:\\ 0\\.003984265875998493\ \(0\)\
\-\ first\\:\\ 0\\.003966090504544747\ \(0\)\
\-\ \\)\\:\\ 0\\.003947649748897953\ \(0\)\
\-\ \\>\\:\\ 0\\.003926926023054723\ \(0\)\
\-\ along\\:\\ 0\\.00390602195969366\ \(0\)\
\-\ often\\:\\ 0\\.0037710560837062967\ \(0\)\
\-\ 2\\.\\:\\ 0\\.003758567277732031\ \(0\)\
\-\ between\\:\\ 0\\.003746190229909051\ \(0\)\
\-\ known\\:\\ 0\\.003740042993725892\ \(0\)\
\-\ any\\:\\ 0\\.0037217635312203233\ \(0\)\
\-\ normal\\:\\ 0\\.0037057052686005564\ \(0\)\
\-\ such\\:\\ 0\\.0036947894741920506\ \(0\)\
\-\ 1\\.\\:\\ 0\\.0036918245730257274\ \(0\)\
\-\ be\\:\\ 0\\.003645246814229403\ \(0\)\
\-\ show\\:\\ 0\\.0036281548194904926\ \(0\)\
\-\ decreased\\:\\ 0\\.0035141858958845913\ \(0\)\
\-\ ultrasound\\:\\ 0\\.003506393616882854\ \(0\)\
\-\ pulmonary\\:\\ 0\\.0034530433059751916\ \(0\)\
\-\ loss\\:\\ 0\\.0034307941527917563\ \(0\)\
\-\ level\\:\\ 0\\.00340648551541761\ \(0\)\
\-\ changes\\:\\ 0\\.0033873415992186177\ \(0\)\
\-\ when\\:\\ 0\\.0033849671336320967\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0033778680973575183\ \(0\)\
\-\ carcinoma\\:\\ 0\\.003349830802234947\ \(0\)\
\-\ time\\:\\ 0\\.0033383142838718017\ \(0\)\
\-\ likely\\:\\ 0\\.0033337343927187504\ \(0\)\
\-\ chronic\\:\\ 0\\.003329169616745505\ \(0\)\
\-\ mass\\:\\ 0\\.0032875823152076476\ \(0\)\
\-\ history\\:\\ 0\\.0032647705054137856\ \(0\)\
\-\ one\\:\\ 0\\.003202947971384017\ \(0\)\
\-\ cell\\:\\ 0\\.003192587429573287\ \(0\)\
\-\ significant\\:\\ 0\\.003178211827184265\ \(0\)\
\-\ lesions\\:\\ 0\\.003163984102827037\ \(0\)\
\-\ therapy\\:\\ 0\\.0031599457762664083\ \(0\)\
\-\ evidence\\:\\ 0\\.003098814084878116\ \(0\)\
\-\ common\\:\\ 0\\.0030930390206865797\ \(0\)\
\-\ metastatic\\:\\ 0\\.0029752550534109133\ \(0\)\
\-\ with\\:\\ 0\\.002912967039582317\ \(0\)\
\-\ increased\\:\\ 0\\.002891403570953881\ \(0\)\
\-\ surgery\\:\\ 0\\.0028699848746338522\ \(0\)\
\-\ the\\:\\ 0\\.0028682424212370496\ \(0\)\
\-\ noted\\:\\ 0\\.002801412432161264\ \(0\)\
\-\ \\;\\:\\ 0\\.002801412432161264\ \(0\)\
\-\ or\\:\\ 0\\.0027704640358608783\ \(0\)\
\-\ was\\:\\ 0\\.002733824404463864\ \(0\)\
\-\ woman\\:\\ 0\\.0027301562205932317\ \(0\)\
\-\ most\\:\\ 0\\.0027286793108272146\ \(0\)\
\-\ other\\:\\ 0\\.002724258020335337\ \(0\)\
\-\ demonstrate\\:\\ 0\\.002719850817888023\ \(0\)\
\-\ can\\:\\ 0\\.002680805466762199\ \(0\)\
\-\ present\\:\\ 0\\.0026694450261848975\ \(0\)\
\-\ year\\:\\ 0\\.0026448278541436093\ \(0\)\
\-\ exam\\:\\ 0\\.0025964508159744652\ \(0\)\
\-\ case\\:\\ 0\\.0025857599348095032\ \(0\)\
\-\ large\\:\\ 0\\.002584429366294716\ \(0\)\
\-\ 2\\:\\ 0\\.0025450961224212257\ \(0\)\
\-\ findings\\:\\ 0\\.0025156804091147436\ \(0\)\
\-\ surgical\\:\\ 0\\.0024844007887295347\ \(0\)\
\-\ no\\:\\ 0\\.002380205119512592\ \(0\)\
\-\ also\\:\\ 0\\.0023300409317706106\ \(0\)\
\-\ has\\:\\ 0\\.0022195020338786693\ \(0\)\
\-\ which\\:\\ 0\\.0022062857361584355\ \(0\)\
\-\ \\.\\:\\ 0\\.0019640130620938463\ \(0\)\
\-\ as\\:\\ 0\\.0017877973802131783\ \(0\)\
\-\ there\\:\\ 0\\.0017589426783748115\ \(0\)\
\-\ not\\:\\ 0\\.0017079096427965912\ \(0\)\
\-\ \\:\\:\\ 0\\.001563312331937296\ \(0\)\
\-\ right\\:\\ 0\\.0012470701370821808\ \(0\)\
\-\ old\\:\\ 0\\.0012101446706255252\ \(0\)\
\-\ patient\\:\\ 0\\.0011847744549327635\ \(0\)\
